Noradrenergic and dopaminergic effects of (+)‐amphetamine‐like stimulants in the baboon Papio anubis

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Synapse

• Publication date

  2005-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/syn.20126PMID 15729739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phentermine inhibition of recombinant human liver monoamine oxidases A and B.

  2002cited by this paper
• Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release

  2001cited by this paper
• Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

  2001cited by this paper
• Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria.

  2001cited by this paper
• Comparison of methods

  2000cited by this paper
• Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors.

  2000cited by this paper
• Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications

  2000cited by this paper
• GBR12909 attenuates amphetamine‐induced striatal dopamine release as measured by [11C]raclopride continuous infusion PET scans

  1999cited by this paper
• Comparison of Methods for the Assessment of Central Nervous System Stimulant Response after Dextroamphetamine Administration to Healthy Male Volunteers

  1996cited by this paper
• Evaluation of Phentermine and Fenfluramine, Alone and in Combination, in Normal, Healthy Volunteers

  1996cited by this paper
• Neurotransmitter transporters: three distinct gene families.

  1993cited by this paper
• Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels

  1993cited by this paper
• Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain

  1991cited by this paper
• Psychostimulants in Psychiatry

  1990cited by this paper
• The use of psychostimulants in general psychiatry. A reconsideration.

  1987cited by this paper
• Dopamine: a prolactin-inhibiting hormone.

  1985cited by this paper
• Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia.

  1983cited by this paper
• Effects of injected sympathomimetic amines on plasma catecholamines and circulatory variables in man.

  1983cited by this paper
• A Collection of Therapeutic, Toxic and Fatal Blood Drug Concentrations in Man

  1983cited by this paper
• Specificity of Endogenous Substrates for Types A and B Monoamine Oxidase in Rat Striatum

  1981influential reference
• Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.

  1979cited by this paper
• Dopaminergic agonist properties of ephedrine-theoretical implications

  1977influential reference
• Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man

  1971cited by this paper

• Anti-obesity weight loss medications: Short-term and long-term use.

  2022cites this paper
• Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat

  2021cites this paper
• Pharmacotherapy for Patients with Obesity.

  2018cites this paper
• Drug Treatment of Obesity: From Bench to Bedside

  2018cites this paper
• The Prevention and Treatment of Adolescent Stimulant and Methamphetamine Use

  2018cites this paper
• Off-label drugs for weight management

  2017cites this paper
• Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice

  2017cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2017cites this paper
• Pharmacotherapy for weight loss

  2017cites this paper
• Metabolic Syndrome and Obesity : Targets and Therapy

  2017cites this paper
• Phentermine-topiramate: First combination drug for obesity

  2015cites this paper
• Targeting oxidative stress in the hypothalamus: the effect of transcription factor STAT3 knockdown on endogenous antioxidants-mediated appetite control

  2014cites this paper
• Postmarketing Surveillance Study of the Efficacy and Safety of Phentermine in Patients with Obesity

  2013cites this paper
• Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

  2013cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Clinical utility of phentermine/topiramate (QsymiaTM) combination for the treatment of obesity

  2013cites this paper
• Role of the Catecholamine and Limbic Systems in Narcolepsy/Cataplexy

  2013cites this paper
• Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

  2013cites this paper
• Pharmacological studies of performance on the free-operant psychophysical procedure.

  2013cites this paper
• Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

  2013cites this paper
• Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

  2013cites this paper
• Postmarketing Surveillance Study of the Efficacy and Safety of Phentermine in Patients with Obesity Original Article

  2013cites this paper
• Phentermine, Sibutramine and Affective Disorders

  2013cites this paper
• Knocking down the transcript of NF-kappaB modulates the reciprocal regulation of endogenous antioxidants and feeding behavior in phenylpropanolamine-treated rats

  2012cites this paper
• A Case of Phentermine Hydrochloride Induced Acute Myopia and Acute Angle Closure

  2011cites this paper
• Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease

  2010cites this paper
• Treatment of Obesity With “Combination” Pharmacotherapy

  2010cites this paper
• The effect of protein kinase C‐delta knockdown on anti‐free radical enzyme and neuropeptide Y gene expression in phenylpropanolamine‐treated rats

  2010cites this paper
• Serotonergic drugs and valvular heart disease

  2009cites this paper
• Roles of protein kinase Cα isozyme in the regulation of oxidative stress and neuropeptide Y gene expression in phenylpropanolamine‐mediated appetite suppression

  2009cites this paper
• Phentermine cardiovascular safety.

  2009cites this paper
• Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

  2009cites this paper
• Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs

  2008cites this paper
• Effects of acute administration of phentermine, alone or in combination with dexfenfluramine, on pain reactivity in the adult rat.

  2008cites this paper
• Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.

  2008cites this paper
• Chapter 19. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions

  2008cites this paper
• Dopamine/serotonin releasers as medications for stimulant addictions.

  2008cites this paper
• Transcriptional interruption of cAMP response element binding protein modulates superoxide dismutase and neuropeptide Y‐mediated feeding behavior in freely moving rats

  2008cites this paper
• Tolerance to the effect of 2,5-dimethoxy-4-iodoamphetamine (DOI) on free-operant timing behaviour: interaction between behavioural and pharmacological mechanisms

  2007cites this paper
• Dual dopamine/serotonin releasers as potential medications for stimulante and alcohol addictions

  2007cites this paper
• Brain imaging research: Does the science serve clinical practice?

  2007cites this paper
• Interrupting activator protein‐1 signaling in conscious rats can modify neuropeptide Y gene expression and feeding behavior of phenylpropanolamine

  2007cites this paper
• Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: Modulation by MAO-inhibition

  2007cites this paper
• Efecto de la D-Anfetamina en un programa de estimación temporal retrospectiva

  2007influential citation
• EFECTO DE LA D-ANFETAMINA EN UN PROGRAMA DE ESTIMACIÓN TEMPORAL RETROSPECTIVA EFFECT OF D-AMPHETAMINE ON A RETROSPECTIVE TIMING TASK

  2007cites this paper
• Transcript of protein kinase A knock-down modulates feeding behavior and neuropeptide Y gene expression in phenylpropanolamine-treated rats.

  2007cites this paper
• Therapeutic potential of monoamine transporter substrates.

  2006cites this paper
• Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease

  2006cites this paper
• Evidence for a role of D1 dopamine receptors in d-amphetamine’s effect on timing behaviour in the free-operant psychophysical procedure

  2006influential citation
• JPET # 101618 2 RUNNING TITLE PAGE Running Title : Amphetamines increase plasma serotonin

  2006cites this paper
• Effects of d-amphetamine and DOI (2,5-dimethoxy-4-iodoamphetamine) on timing behavior: interaction between D1 and 5-HT2A receptors

  2006cites this paper
• Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People

  2006cites this paper
• Structure-activity relationships of substituted N-benzyl piperidines in the GBR series: Synthesis of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(2-trifluoromethylbenzyl)piperidine, an allosteric modulator of the serotonin transporter.

  2006cites this paper
• Dopamine-mediated actions of ephedrine in the rat substantia nigra.

  2006cites this paper